Management of Insomnia in Breast Cancer Patients
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Insomnia Sleep Studies, Other Indications |
| Therapuetic Areas: | Oncology, Psychiatry / Psychology, Other |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 12/1/2018 |
| Start Date: | January 2011 |
| End Date: | July 2016 |
Management of Insomnia in Breast Cancer Patients: A Preliminary Pilot Study
To provide preliminary data on the effects of brief behavioral therapy for insomnia (BBT-I)
on insomnia in breast cancer patients expecting to receive cancer treatment (unspecified).
Participants will be randomized into 4 groups:
- Arm 1: Brief Behavioral Treatment of Insomnia (BBT-I) + Armodafinil 150 mg/day.
- Arm 2: Behavioral therapy for insomnia (CBT-I) + Armodafinil 150 mg/day.
- Arm 3: Brief Behavioral Treatment of Insomnia (BBT-I) without pharmaceutical
intervention.
- Arm 4: Behavioral therapy for insomnia (CBT-I) without pharmaceutical intervention.
on insomnia in breast cancer patients expecting to receive cancer treatment (unspecified).
Participants will be randomized into 4 groups:
- Arm 1: Brief Behavioral Treatment of Insomnia (BBT-I) + Armodafinil 150 mg/day.
- Arm 2: Behavioral therapy for insomnia (CBT-I) + Armodafinil 150 mg/day.
- Arm 3: Brief Behavioral Treatment of Insomnia (BBT-I) without pharmaceutical
intervention.
- Arm 4: Behavioral therapy for insomnia (CBT-I) without pharmaceutical intervention.
The purpose of this study is to test the efficacy of Brief Behavioral Treatment of Insomnia
(BBT-I) in the treatment of insomnia in humans.
Insomnia is an extraordinarily common problem for cancer patients that is often associated
with diminished social and vocational functioning and QOL. It is also likely that insomnia
exacerbates other cancer-related symptoms (eg, fatigue, nausea, depressive mood, pain and/or
reduced pain tolerance) and thus gives rise to the possibility of additive or multiplicative
interactions. It is possible that untreated insomnia in the context of cancer therapy may
lead to chronic forms of insomnia in cancer survivors which, in turn, independently confers
risk for increased psychiatric and medical morbidity.
Thus, insomnia, by itself, is a significant problem that requires better understanding in
order that its high prevalence can be reduced.
Developing interventions that might prevent onset of insomnia in breast cancer patients is
vital.
(BBT-I) in the treatment of insomnia in humans.
Insomnia is an extraordinarily common problem for cancer patients that is often associated
with diminished social and vocational functioning and QOL. It is also likely that insomnia
exacerbates other cancer-related symptoms (eg, fatigue, nausea, depressive mood, pain and/or
reduced pain tolerance) and thus gives rise to the possibility of additive or multiplicative
interactions. It is possible that untreated insomnia in the context of cancer therapy may
lead to chronic forms of insomnia in cancer survivors which, in turn, independently confers
risk for increased psychiatric and medical morbidity.
Thus, insomnia, by itself, is a significant problem that requires better understanding in
order that its high prevalence can be reduced.
Developing interventions that might prevent onset of insomnia in breast cancer patients is
vital.
INCLUSION CRITERIA
- Be scheduled for cancer treatment with chemotherapy or biologics (prior chemotherapy
and/or diagnosis of metastatic breast are allowed)
- Have at least 6 weeks of treatment remaining
- ≥ 21 years old
- Able to understand written and spoken English
- Able to swallow medication (until amendment omitting armodafinil treatment)
- Score of 3+ on the Sleep Disruption Evaluation form, OR a score of 8+ on Insomnia
Severity Index (ISI)
EXCLUSION CRITERIA
- Prior treatment with armodafinil or modafinil (until amendment omitting armodafinil
treatment)
- Prior treatment with psycho-stimulant medication within the past 28 days (until
amendment omitting armodafinil treatment)
- Prior treatment with antiseizure medications (until amendment omitting armodafinil
treatment)
- Has continuously taken sleep medication daily for the last 28 days (until amendment
omitting armodafinil treatment)
- History (self-reported) of unstable medical or psychiatric illness (within the last 5
years)
- History of uncontrolled, cardiac disease, hypertension, severe headaches, glaucoma, or
seizures (until amendment omitting armodafinil treatment)
- Pregnant or nursing
- History of substance abuse or meet criteria for current alcohol abuse or dependence
- History (self-reported) of chronic, preexisting insomnia, sleep apnea, or restless leg
syndrome (RLS)
- Severe hepatic impairment (until amendment omitting armodafinil treatment)
We found this trial at
1
site
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
Click here to add this to my saved trials
